Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028161518> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2028161518 endingPage "130" @default.
- W2028161518 startingPage "121" @default.
- W2028161518 abstract "Objective:Bilastine is a non-sedating second-generation H1 antihistamine with proven efficacy and safety in the treatment of patients with seasonal allergic rhinitis and urticaria. The objective of this study was to demonstrate the efficacy and safety of bilastine in patients with perennial allergic rhinitis (PAR).Methods:In a multicenter, randomized, placebo-controlled, double-blind, parallel-group study, patients with symptomatic PAR (n = 650) from Argentina, Europe, and South Africa received bilastine 20 mg, cetirizine 10 mg, or placebo once daily for 4 weeks. The primary efficacy outcome was the mean area under the curve (AUC) of reflective total 6-symptom scores (rT6SS) from baseline visit to day 28 (D28). Secondary outcome measures included mean AUC of instantaneous total 6-symptom scores (iT6SS), and mean AUCs of reflective and instantaneous total 4-nasal symptom scores (T4NSS) and total 2-ocular symptom scores (T2OSS) from baseline to D28. An open-label extension phase evaluated the safety of bilastine 20 mg administered to patients (n = 513) for one year.Results:In the overall population no significant differences in efficacy outcomes were found between active treatments and placebo. On account of the high placebo response in South Africa, a post-hoc analysis was conducted. This analysis demonstrated that statistically significant differences existed between active treatments and placebo in the mean AUC of rT6SS (p < 0.05) and T4NSS (p < 0.02), respectively, from baseline to D28 visit for the intent-to-treat population in patients from Europe and Argentina, whereas the difference was not statistically significant in South Africa. Whether this is related to differences in the demographic or clinical characteristics of South African patients (they had PAR for longer and reported more severe symptoms) and/or the disease management process compared with their European and Argentinean counterparts warrants further investigation.Conclusions:A post-hoc analysis indicated that bilastine and cetirizine were similarly effective and more effective than placebo during a 4-week treatment period in patients with PAR. In addition, bilastine was shown to be safe and well-tolerated over a 1-year treatment period.Clinical trial registry number:NCT01127620." @default.
- W2028161518 created "2016-06-24" @default.
- W2028161518 creator A5006107863 @default.
- W2028161518 creator A5015841967 @default.
- W2028161518 creator A5083049912 @default.
- W2028161518 creator A5089377771 @default.
- W2028161518 date "2011-11-30" @default.
- W2028161518 modified "2023-10-09" @default.
- W2028161518 title "Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis" @default.
- W2028161518 cites W1596034103 @default.
- W2028161518 cites W1965342950 @default.
- W2028161518 cites W1973974516 @default.
- W2028161518 cites W1976073672 @default.
- W2028161518 cites W2000455036 @default.
- W2028161518 cites W2026757305 @default.
- W2028161518 cites W2032148343 @default.
- W2028161518 cites W2047604583 @default.
- W2028161518 cites W2057654836 @default.
- W2028161518 cites W2059332672 @default.
- W2028161518 cites W2063594663 @default.
- W2028161518 cites W2124616677 @default.
- W2028161518 cites W2128180999 @default.
- W2028161518 cites W2164132449 @default.
- W2028161518 cites W86738069 @default.
- W2028161518 doi "https://doi.org/10.1185/03007995.2011.640667" @default.
- W2028161518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22077106" @default.
- W2028161518 hasPublicationYear "2011" @default.
- W2028161518 type Work @default.
- W2028161518 sameAs 2028161518 @default.
- W2028161518 citedByCount "51" @default.
- W2028161518 countsByYear W20281615182012 @default.
- W2028161518 countsByYear W20281615182013 @default.
- W2028161518 countsByYear W20281615182014 @default.
- W2028161518 countsByYear W20281615182015 @default.
- W2028161518 countsByYear W20281615182016 @default.
- W2028161518 countsByYear W20281615182017 @default.
- W2028161518 countsByYear W20281615182018 @default.
- W2028161518 countsByYear W20281615182019 @default.
- W2028161518 countsByYear W20281615182020 @default.
- W2028161518 countsByYear W20281615182021 @default.
- W2028161518 countsByYear W20281615182022 @default.
- W2028161518 countsByYear W20281615182023 @default.
- W2028161518 crossrefType "journal-article" @default.
- W2028161518 hasAuthorship W2028161518A5006107863 @default.
- W2028161518 hasAuthorship W2028161518A5015841967 @default.
- W2028161518 hasAuthorship W2028161518A5083049912 @default.
- W2028161518 hasAuthorship W2028161518A5089377771 @default.
- W2028161518 hasConcept C126322002 @default.
- W2028161518 hasConcept C142724271 @default.
- W2028161518 hasConcept C197934379 @default.
- W2028161518 hasConcept C204787440 @default.
- W2028161518 hasConcept C27081682 @default.
- W2028161518 hasConcept C2776880894 @default.
- W2028161518 hasConcept C2779463773 @default.
- W2028161518 hasConcept C2908647359 @default.
- W2028161518 hasConcept C42219234 @default.
- W2028161518 hasConcept C67761136 @default.
- W2028161518 hasConcept C71924100 @default.
- W2028161518 hasConcept C90924648 @default.
- W2028161518 hasConcept C99454951 @default.
- W2028161518 hasConceptScore W2028161518C126322002 @default.
- W2028161518 hasConceptScore W2028161518C142724271 @default.
- W2028161518 hasConceptScore W2028161518C197934379 @default.
- W2028161518 hasConceptScore W2028161518C204787440 @default.
- W2028161518 hasConceptScore W2028161518C27081682 @default.
- W2028161518 hasConceptScore W2028161518C2776880894 @default.
- W2028161518 hasConceptScore W2028161518C2779463773 @default.
- W2028161518 hasConceptScore W2028161518C2908647359 @default.
- W2028161518 hasConceptScore W2028161518C42219234 @default.
- W2028161518 hasConceptScore W2028161518C67761136 @default.
- W2028161518 hasConceptScore W2028161518C71924100 @default.
- W2028161518 hasConceptScore W2028161518C90924648 @default.
- W2028161518 hasConceptScore W2028161518C99454951 @default.
- W2028161518 hasIssue "1" @default.
- W2028161518 hasLocation W20281615181 @default.
- W2028161518 hasLocation W20281615182 @default.
- W2028161518 hasOpenAccess W2028161518 @default.
- W2028161518 hasPrimaryLocation W20281615181 @default.
- W2028161518 hasRelatedWork W135838772 @default.
- W2028161518 hasRelatedWork W142874572 @default.
- W2028161518 hasRelatedWork W1486820001 @default.
- W2028161518 hasRelatedWork W1550003171 @default.
- W2028161518 hasRelatedWork W2059012840 @default.
- W2028161518 hasRelatedWork W2153100015 @default.
- W2028161518 hasRelatedWork W2407599001 @default.
- W2028161518 hasRelatedWork W2607337784 @default.
- W2028161518 hasRelatedWork W2751938426 @default.
- W2028161518 hasRelatedWork W2884867322 @default.
- W2028161518 hasVolume "28" @default.
- W2028161518 isParatext "false" @default.
- W2028161518 isRetracted "false" @default.
- W2028161518 magId "2028161518" @default.
- W2028161518 workType "article" @default.